|
For those that are just joining us, welcome. If this is your 1st email from TopNasdaqStocks.com the timing could not be any better.
Pluristem Therapeutics (PSTI) has been hitting the ground running this month and so far a strong mix of momentum and previous announcements have spurred a lot more activity with this little biotech. But today things could start getting even more exciting. Why? This morning PSTI announced even more positive news that could continue to build on its previous news from earlier this month.
Pluristem Participates in Radiation Injury Treatment Network Conference Co-sponsored by National Institutes of Health’s NIAID
HAIFA, Israel, July 20, 2016 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced its participation in the Radiation Injury Treatment Network’s meeting titled, “Medical Management of Radiation Casualties: Where Research and Usage Meet”. The meeting, which took place on July 18-19, 2016, was organized jointly by the Radiation Injury Treatment Network and the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID).
Racheli Ofir, Ph.D., Pluristem’s Vice President of Research & Intellectual Property, shared her expertise in studying the treatment of Acute Radiation Syndrome (ARS) in a variety of animal models.
“We are pleased to have been invited to participate in this important event. It highlights our continued collaboration with the NIH’s NIAID to develop PLX-R18 as a treatment for the hematologic component of ARS,” said Zami Aberman, Chairman and CEO of Pluristem Therapeutics.
Pluristem’s scientists, together with researchers at several academic institutions, Hadassah Medical Center and at the NIAID, have studied the Company’s PLX-R18 cells as a potential treatment for the hematologic subsyndrome of ARS. They have also used animal and in vitro models to delineate the unique mechanism of action of PLX-R18 in this indication. Data have demonstrated that PLX-R18 cells release a spectrum of therapeutic proteins in response to inflammatory cytokines secreted by animals with acutely damaged bone marrow caused by exposure to high levels of radiation. The therapeutic proteins from PLX-R18 cells work to stimulate recovery of hematopoietic function, addressing production of all three blood cell lineages.
As previously announced, the U.S. FDA recently cleared Pluristem’s Phase I trial of PLX-R18 in the treatment of insufficient hematopoietic recovery following hematopoietic cell transplantation.
With the 3 month high still in the distance, there may be much more room to run so keep a close eye on PSTI and a close watch on your inbox for more updates on our newest biotech beast!
If You Have Yet To Do So, Click Here & Access Our Full PSTI Report NOW!
With the way the biotech space has been exploding lately, it wouldn't be a surprise to see PSTI follow suit in our opinion. Download the full PSTI report HERE and be ready for this morning's opening bell.
Want To Get Our Alerts In Real Time?
Text Messages Are Received Much Quicker Than Email So If You Have A Cell Phone, Take It Out And Text The Word “NASDAQ” to 77948
|
